Novan Inc
F:6LUA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
People's Insurance Company Group of China Ltd
OTC:PINXF
|
CN |
|
Lithium Universe Ltd
ASX:LU7
|
AU |
|
Sino Hotels (Holdings) Ltd
HKEX:1221
|
HK |
|
Ependion AB
STO:EPEN
|
SE |
|
Fathom Holdings Inc
NASDAQ:FTHM
|
US |
|
Viatris Inc
NASDAQ:VTRS
|
US |
|
Copenhagen Capital A/S
CSE:CPHCAP ST
|
DK |
|
S
|
SGA Solutions Co Ltd
KOSDAQ:184230
|
KR |
|
Jahez International Company for Information Systems Technology SCJSC
SAU:9526
|
SA |
|
Universal Apparel & Textile Co
OTC:DKGR
|
US |
|
Globe Kita Terang Tbk PT
IDX:GLOB
|
ID |
|
IAMGOLD Corp
TSX:IMG
|
CA |
|
Parken Sport & Entertainment A/S
CSE:PARKEN
|
DK |
|
E
|
EBR Systems Inc
ASX:EBR
|
US |
|
Hanover Insurance Group Inc
NYSE:THG
|
US |
|
P
|
P10 Inc
NYSE:PX
|
US |
|
Silicom Ltd
NASDAQ:SILC
|
IL |
|
Reenova Investment Holding Ltd
SGX:5EC
|
SG |
|
HMS Networks AB
STO:HMS
|
SE |
|
Doman Building Materials Group Ltd
TSX:DBM
|
CA |
|
C
|
Covivio Hotels SCA
LSE:0IS8
|
FR |
|
X Fab Silicon Foundries EV
PAR:XFAB
|
BE |
Novan Inc
Research & Development
Novan Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Novan Inc
F:6LUA
|
Research & Development
-$16m
|
CAGR 3-Years
14%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Research & Development
-$14.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-5%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Research & Development
-$9.5B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-5%
|
|
|
Pfizer Inc
NYSE:PFE
|
Research & Development
-$10.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Research & Development
-$15.6B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-9%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Research & Development
-$13.3B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-11%
|
|
Novan Inc
Glance View
Novan, Inc. is a biotechnology company, which engages in leveraging nitric oxide’s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. The company is headquartered in Durham, North Carolina and currently employs 29 full-time employees. The company went IPO on 2016-09-21. The firm is engaged in researching, developing and marketing products for skin diseases. The firm is focused on dermatology and anti-infective therapies. Its technology platform leverages nitric oxide’s naturally occurring anti-viral, anti-bacterial, anti-fungal, and immunomodulatory mechanisms of action to treat a range of diseases. The firm has clinical-stage dermatology and anti-infective drug candidates with multi-factorial (SB204), anti-viral (SB206), anti-fungal (SB208), and anti-inflammatory (SB414) mechanisms of action. The Company’s lead product candidate is SB206, which is a topical gel with anti-viral properties for the treatment of viral skin infections, with focus on molluscum contagiosum. The firm is exploring the potential of its NITRICIL technology as a potential treatment option for COVID-19, targeting the reduction of viral shedding and transmission.
See Also
What is Novan Inc's Research & Development?
Research & Development
-16m
USD
Based on the financial report for Dec 31, 2022, Novan Inc's Research & Development amounts to -16m USD.
What is Novan Inc's Research & Development growth rate?
Research & Development CAGR 5Y
9%
Over the last year, the Research & Development growth was 22%. The average annual Research & Development growth rates for Novan Inc have been 14% over the past three years , 9% over the past five years .
